Ten Capital Wealth Advisors’s Protalix BioTherapeutics PLX Stock Holding History

Ten Capital Wealth Advisors’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,000	Closed	-$1.37K	–	636
2022 Q4	$1.37K	Buy	1,000 +110	+12%	+$121	﹤0.01%	459
2022 Q3	$1K	Buy	890 +100	+13%	+$111	﹤0.01%	526
2022 Q2	$1K	Hold	790	–	–	﹤0.01%	431
2022 Q1	$1K	Buy	790 +140	+22%	+$128	﹤0.01%	455
2021 Q4	$1K	Buy	650 +98	+18%	+$103	﹤0.01%	454
2021 Q3	$1K	Buy	552 +227	+70%	+$345	﹤0.01%	410
2021 Q2	$1K	Buy	325 +125	+63%	+$430	﹤0.01%	454
2021 Q1	$0	Buy	+200	New	+$931	﹤0.01%	389

Other funds holding PLX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ten Capital Wealth Advisors's PLX Position: Q1 2023 in Review

Ten Capital Wealth Advisors sold out of Protalix BioTherapeutics (PLX) in Q1 2023, closing a stake of 1,000 shares — an estimated $1.37K sold.

Ten Capital Wealth Advisors first reported a position in PLX in Q1 2021 and held it in 8 quarters. The position peaked at $1.37K in Q4 2022. 34 funds tracked by Wall St. Rank hold PLX as of Q1 2023.

Ten Capital Wealth Advisors reported no remaining Protalix BioTherapeutics position as of Q1 2023 after selling out during the quarter.
Ten Capital Wealth Advisors sold 1,000 Protalix BioTherapeutics shares in Q1 2023, an estimated $1.37K.
Ten Capital Wealth Advisors first reported a position in Protalix BioTherapeutics in Q1 2021 and held it in 8 quarters.
Ten Capital Wealth Advisors's Protalix BioTherapeutics position peaked at $1.37K in Q4 2022.
34 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2023.

Based on Ten Capital Wealth Advisors's 13F filing for Q1 2023, filed 4 May 2023.